MacroCure Biotech Company Files For Nasdaq IPO

June 25, 2014 | The biotechnology company MacroCure reportedly will file for a Nasdaq public offering to raise several tens of millions of dollars on Wall Street. According to a “Globes” report, the IPO is being underwritten by Credit Suisse Group, Jefferies LLC, Oppenheimer & Co and Nomura Securities International. MacroCure, based in Petah Tikvah, has developed a method for treating wounds using white blood cells taken from donor blood. According to the company, their Curexell treatment showed a 90 percent reduction rate in patients with deep wound infections.